WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced preliminary revenue results for the fourth quarter and fiscal year ended December 31, 2006. The Company expects to record total fourth quarter revenues of approximately $18 million, with approximately $12 million from ANTARA(R) (fenofibrate) capsules and approximately $6 million in revenues related to FACTIVE(R) (gemifloxacin mesylate) tablets. These results reflect the first full quarter of sales for ANTARA, which was acquired by Oscient during the third quarter of 2006, and compare with $9.4 million in total revenues in the fourth quarter of 2005.
